These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9838964)

  • 21. A post-marketing observational study to assess the safety of mibefradil in the community in England.
    Riley J; Wilton LV; Shakir SA
    Int J Clin Pharmacol Ther; 2002 Jun; 40(6):241-8. PubMed ID: 12078937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mibefradil: a new twist to the calcium channel antagonist.
    Lynn MM
    Nurse Pract; 1998 May; 23(5):100, 102-4, 106-7. PubMed ID: 9614683
    [No Abstract]   [Full Text] [Related]  

  • 24. [Mibefradil: a new class calcium inhibitor].
    Internist (Berl); 1996 Oct; 37(10 Suppl Mibefradil):1-8. PubMed ID: 9402420
    [No Abstract]   [Full Text] [Related]  

  • 25. Mibefradil: the sole exception.
    Weerasuriya K
    Lancet; 1998 Sep; 352(9130):823-4. PubMed ID: 9737324
    [No Abstract]   [Full Text] [Related]  

  • 26. Roche, FDA announce new drug-interaction warnings for mibefradil.
    Am J Health Syst Pharm; 1998 Feb; 55(3):210. PubMed ID: 9492249
    [No Abstract]   [Full Text] [Related]  

  • 27. Mibefradil: "Has the baby been thrown out with the bath water?".
    Beltrame JF; Turner SP; Leslie S; Horowitz JD
    Am Heart J; 2003 Jul; 146(1):e3. PubMed ID: 12851630
    [No Abstract]   [Full Text] [Related]  

  • 28. Hemolysis on intravenous administration of a new calcium antagonist.
    Kleinbloesem CH; Siepmann M; Kirch W
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):855-8. PubMed ID: 7564328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells.
    Rossier MF; Ertel EA; Vallotton MB; Capponi AM
    J Pharmacol Exp Ther; 1998 Dec; 287(3):824-31. PubMed ID: 9864260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical researchers and pharmaceutical industry. The examples of troglitazone and mibefradil].
    Bouvy ML; Egberts AC; Leufkens HG
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1727-9. PubMed ID: 10494317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-drug interactions of new active substances: mibefradil example.
    Krayenbühl JC; Vozeh S; Kondo-Oestreicher M; Dayer P
    Eur J Clin Pharmacol; 1999 Oct; 55(8):559-65. PubMed ID: 10541773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man.
    Wiltshire HR; Sutton BM; Heeps G; Betty AM; Angus DW; Harris SR; Worth E; Welker HA
    Xenobiotica; 1997 Jun; 27(6):557-71. PubMed ID: 9211656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus toxicity due to drug interaction with mibefradil in a patient after liver transplantation.
    Ocran KW; Plauth M; Mai I; Lochs H
    Z Gastroenterol; 1999 Oct; 37(10):1025-8. PubMed ID: 10549098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug reactions and interactions].
    D'Arcy PF
    J Pharm Belg; 1987; 42(6):404-8. PubMed ID: 2895807
    [No Abstract]   [Full Text] [Related]  

  • 35. Capillary blood cell velocity in finger nailfold: effect of enalapril and mibefradil in patients with mild to moderate hypertension.
    Martina B; Frach B; Surber C; Drewe J; Battegay E; Gasser P
    Microvasc Res; 1999 Mar; 57(2):94-9. PubMed ID: 10049657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug surveillance note. Telangiectasis and calcium antagonists].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 1999; 126(6-7):546. PubMed ID: 10495872
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of mibefradil, a blocker of T-type Ca2+ channels, in single myocytes and intact muscle of guinea-pig heart.
    Emanuel K; Mackiewicz U; Pytkowski B; Lewartowski B
    J Physiol Pharmacol; 1998 Dec; 49(4):577-90. PubMed ID: 10069698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety of newly approved medicines: do recent market removals mean there is a problem?
    Friedman MA; Woodcock J; Lumpkin MM; Shuren JE; Hass AE; Thompson LJ
    JAMA; 1999 May; 281(18):1728-34. PubMed ID: 10328074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the T-type calcium channel blockade with oral mibefradil on the electrophysiologic properties of the human heart.
    Mádle A; Linhartová K; Koza J
    Med Sci Monit; 2001; 7(1):74-7. PubMed ID: 11208497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Cav1.2.
    Moosmang S; Haider N; Brüderl B; Welling A; Hofmann F
    Circ Res; 2006 Jan; 98(1):105-10. PubMed ID: 16306443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.